A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she lives in Wales says she "wants a chance to live". Rachel Davies, 40, from ...

DCC shares have jumped 17% in the FTSE 100 index after the Dublin-based conglomerate announced plans to focus on its energy ...

Also in today’s newsletter, US regulators plan to investigate Microsoft’s cloud business, and Disney-Reliance Indian media giant says TV ‘is not dead’ ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of p18,000.00. Justin Smith has given his Buy rating due to a combination of ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Cambridge, England-based biopharmaceutical giant AstraZeneca is pouring billions of dollars into properties in the United ...